Amylyx Pharmaceuticals Inc (AMLX)vsNovartis AG ADR (NVS)
AMLX
Amylyx Pharmaceuticals Inc
$23.35
-1.18%
HEALTHCARE · Cap: $2.26B
NVS
Novartis AG ADR
$154.61
-1.48%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates -8525363% more annual revenue ($56.69B vs $-665,000). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
AMLX
Avoid33
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMLX.
Margin of Safety
-63.9%
Fair Value
$92.92
Current Price
$154.61
$61.69 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Trading at 9.5x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : AMLX
The primary concerns for AMLX are Price/Book, EPS Growth, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?